Insurance companies would have their claws in any potential new healthcare law so deep, the law will have slash marks on it.
Especially when healthcare CEOs discus political issues with analysts and reporters.
Here's your very own bank earnings 'cheat sheet.'
At the very least, the valuation may be morphing from traditional old school media to a blend of media and tech.
The current picture of mixed action for a market still very close to its all-time highs is something to watch.
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
These stocks are too hot. There's just not enough money chasing hotness.
Pinterest isn't exactly bringing the power to the people.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
The advantage goes to P&G as the larger of the two behemoths in consumer staples has been posting stronger results of late.